Fortrea (FTRE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$20.46-1.78%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · FTRE
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“Fortrea delivered another quarter of progress on our return-to-growth strategy, reflecting stronger commercial execution, continued operational improvements and financial discipline,” said Anshul Th…
Stated in 4 of 4 supplied quarters. Management reported: ““Fortrea delivered another quarter of progress on our return-to-growth strategy, reflecting stronger commercial execution, continued operational improvements and financial discipline,” said Anshul Thakral, CEO of Fortrea.” “"We delivered solid operating and financial performance, including our fourth consecutive quarter with a book-to-bill ratio above 1.0x, and raised our full-year 2026 guidance to reflect our confidence in the business.” Revenue was $691.500 million in 2026-Q3.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
““Fortrea delivered another quarter of progress on our return-to-growth strategy, reflecting stronger commercial execution, continued operational improvements and financial discipline,” said Anshul Th…”
“"We delivered solid operating and financial performance, including our fourth consecutive quarter with a book-to-bill ratio above 1.0x, and raised our full-year 2026 guidance to reflect our confidenc…”
““We started the year strong, focused on delivering for our clients with excellence and making advances in our strategic journey back to growth and margin expansion,” said Anshul Thakral, CEO of Fortr…”
“We have continued to deliver and innovate, beginning the new year on strong footing for our journey back to growth and margin expansion.””
We remain focused on translating stronger demand into revenue growth, margin expansion and long-term shareholder value.”
Stated in 4 of 4 supplied quarters. Management reported: “We remain focused on translating stronger demand into revenue growth, margin expansion and long-term shareholder value.”” “2026 Financial Guidance The Company increased its guidance for the full-year 2026, targeting revenues in the range of $2,620 million to $2,690 million and adjusted EBITDA in the range of $205 million to $220 million.” Operating income was $15.000 million in 2026-Q3.
“We remain focused on translating stronger demand into revenue growth, margin expansion and long-term shareholder value.””
“We remain focused on commercial execution, operational excellence and financial discipline as we continue our strategic journey toward sustainable growth and margin expansion."”
““We started the year strong, focused on delivering for our clients with excellence and making advances in our strategic journey back to growth and margin expansion,” said Anshul Thakral, CEO of Fortr…”
“We have continued to deliver and innovate, beginning the new year on strong footing for our journey back to growth and margin expansion.””
“Our sustained bookings momentum is building a foundation for growth, while targeted investments in early clinical development and technology enhance our ability to deliver differentiated value to cl…
Stated in 3 of 4 supplied quarters. Management reported: ““Our sustained bookings momentum is building a foundation for growth, while targeted investments in early clinical development and technology enhance our ability to deliver differentiated value to clients.” “Our commercial traction across biotech and large pharma c lients underscores we are on the right track.”
““Our sustained bookings momentum is building a foundation for growth, while targeted investments in early clinical development and technology enhance our ability to deliver differentiated value to cl…”
“"We delivered solid operating and financial performance, including our fourth consecutive quarter with a book-to-bill ratio above 1.0x, and raised our full-year 2026 guidance to reflect our confidenc…”
“Our commercial traction across biotech and large pharma c lients underscores we are on the right track.”
Make targeted investments in early clinical development, technology and employees to strengthen client solutions.
Focus on commercial execution and strategic growth to stabilize and increase revenue over time.
Over the trailing year it converted 0.20x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
16 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.